BYD
27.2.2024 16:21:34 CET | Business Wire | Press release
At the Geneva Motor Show on February 26, the World Car Awards announced the top three finalists for 2024. BYD's models, the BYD SEAL and the BYD DOLPHIN, excelled among a host of competitors, securing spots in the top three for the "World Car of the Year" and "World Urban Car" categories, respectively, and progressing to the final round of the competition. BYD makes history as the first and only Chinese carmaker to be shortlisted in the top three for the "World Car of the Year" category.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240227393340/en/
BYD SEAL shortlisted in the Top 3 for the "World Car of the Year" category (Photo: Business Wire)
Regarded as the top three automotive accolades globally, the "World Car Awards," "European Car of the Year," and "North American Car of the Year" are highly esteemed. Dubbed the "Oscars of the automotive world", the "World Car Awards" is particularly celebrated for its emphasis on international models, positioning it as a highly anticipated event within the global automotive industry. BYD's exceptional performance highlights its status as a global leader in the New Energy Vehicle space.
These two models, with their distinctive design, cutting-edge technology, and robust safety features, captured the interest of over 100 automotive media experts from 29 countries. In 2023, the BYD SEAL and BYD DOLPHIN achieved five-star ratings in Euro NCAP and ANCAP tests. Notably, BYD SEAL was also nominated for the final European Car of the Year 2024.
As a frontrunner in the new energy vehicle sector, BYD achieved a milestone with over 3 million new energy vehicle sales in 2023, securing the top spot in global sales, for the second year in a row and breaking into the top ten global automotive brands — a first for a Chinese automaker.
So far, BYD's new energy vehicles have a substantial presence across over 70 countries and regions on six continents, encompassing more than 400 cities. In 2023, BYD emerged as a frontrunner in new energy vehicle sales across various international markets, including Thailand, Singapore, Colombia, and Brazil, garnering extensive consumer acclaim and preference.
Aligning with the World Car Awards' mission to foster continual innovation in the automotive sector, BYD is committed to building a comprehensive zero-emission new energy solution through technological innovations. It aims to enhance consumer travel experiences, spearhead the new energy vehicle industry's growth, and actively contribute to the automotive industry's transformation and progress. Looking ahead, BYD will steadfastly pursue its vision to "Cool the Earth by 1°C," continually driving the industry's green and low-carbon transformation and global sustainable development.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240227393340/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
SLB Launches ExaCT Electrical Downhole CT Control System24.8.2026 13:02:00 CEST | Press release
New platform brings real-time electrical control to coiled tubing intervention, enabling greater precision, visibility and efficiency across intervention operations SLB (NYSE: SLB) today launched the ExaCT™ electrical downhole coiled tubing (CT) control system, an advanced intervention platform that introduces real-time electrical control to coiled tubing operations. By replacing pressure-dependent hydraulic actuation with electrical communication, power delivery and telemetry, the ExaCT system gives operators greater visibility, precision and control, helping improve intervention execution and reservoir access. The ExaCT system combines electrical power, telemetry and downhole measurements to enable communication with, actuation of and verification of downhole tools throughout an intervention. Continuous communication across the toolstring enables on-demand tool actuation across a wide range of intervention applications, including extended-reach and multilateral wells. The increased p
Wolters Kluwer Transforms Trusted Legal Content Into Structured, AI-Ready Intelligence That Powers the Next Wave of Legal AI24.8.2026 13:01:00 CEST | Press release
By transforming authoritative legal content into structured legal intelligence, Wolters Kluwer gives AI the context and relationships needed to deliver deeper research and higher-quality results Wolters KluwerLegal & Regulatory today announced the next evolution of Libra by Wolters Kluwer, its all-in-one Legal AI Workspace. By transforming authoritative legal sources, expert commentaries, and practical guidance into structured legal intelligence, Wolters Kluwer is making the relationships across the full breadth of its expert legal sources more explicit. This will enable deeper contextual research, more comprehensible answers, and workflow-ready results across legal work. Following the integration of Wolters Kluwer content into the Libra AI workspace in the first half of 2026, laws, rulings, expert commentaries, and practical guidance will now be linked to one another and to the matter at hand, creating a connected knowledge graph of expert-curated and authoredlegal knowledge that AI c
Daiichi Sankyo Appoints Markus Kosch to Lead Europe Business as Part of New Commercialization Organization24.8.2026 10:00:00 CEST | Press release
Daiichi Sankyo (TSE: 4568) today announced the appointment of Markus Kosch, MD, as Head of Europe Business, effective April 1, 2027. In this role, he will lead the company's European business within the new globally integrated Commercialization Unit and serve as General Manager of Daiichi Sankyo Europe GmbH, with legal responsibility for the company in Europe. The appointment reflects the next phase of growth of Daiichi Sankyo under its Five-Year Business Plan and the establishment of a new Commercialization Unit. Within this new structure, Markus Kosch will bring together the Oncology and Specialty businesses in Europe under one integrated leadership model to help bring innovative medicines to more patients across the region. For the past five years, Markus Kosch has led the Daiichi Sankyo Oncology Business Division in Europe and Canada, overseeing a period of significant growth and preparing the organization for an increasingly expanding oncology portfolio. Prior to joining Daiichi S
European Commission Approves DAYBU® (trofinetide) as the First and Only Treatment for Neurobehavioral Symptoms of Rett Syndrome in the European Union24.8.2026 09:01:00 CEST | Press release
Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that the European Commission (EC) has granted marketing authorization for DAYBU (trofinetide) for the treatment of neurobehavioral symptoms of Rett syndrome in adults and pediatric patients aged five years and older, making it the first and only treatment approved for Rett syndrome in the European Union (EU). “The approval of DAYBU marks a significant milestone for the Rett syndrome community in the EU and advances our mission to bring this innovative treatment to patients and families who have long faced a profound unmet medical need,” said Catherine Owen Adams, Acadia’s Chief Executive Officer. “For people living with Rett syndrome, a devastating rare neurodevelopmental disorder, there have been no approved treatment options in the EU. We are proud to make DAYBU available and look forward to supporting patients, caregivers, and healthcare providers gain access to treatment." The DAYBU marketing authorization in the EU is prim
ORZEYFUL (oveporexton) Approved in Japan as the First and Only Medicine to Treat the Underlying Cause of Narcolepsy Type 124.8.2026 08:36:00 CEST | Press release
Discovered by Takeda in Japan, ORZEYFUL has the Potential to Redefine Care Beyond Individual Symptom Management for Adults Living with Narcolepsy Type 1 (NT1) Landmark Phase 3 Studies Demonstrated Significant and Meaningful Improvements Across the Full Range of NT1 Symptoms Evaluated in Clinical Trials Compared to Placebo Milestone Marks Third Major Regulatory Approval Secured for ORZEYFUL Around the World Takeda (TOKYO:4502/NYSE:TAK) announced that the Japanese Ministry of Health, Labour and Welfare (MHLW) approved the use of ORZEYFUL (oveporexton) for the treatment of narcolepsy type 1 (NT1, narcolepsy with cataplexy) in adults. ORZEYFUL is a first-in-class oral orexin receptor 2 (OX2R) agonist and the only medicine indicated in Japan to treat the disease holistically rather than individual symptoms. The discovery of this new class of medicine originated in Takeda's laboratories in Japan. Takeda is proceeding with launch preparations and expects to make ORZEYFUL available as quickly
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom